Background: T cell receptor zeta chain (TCRζ) plays a critical role in signal transduction via TCR. Defective signaling through TCRζ-CD3 components may disrupt peripheral T cell tolerance to autoantigen, giving rise to a variety of autoimmune diseases. The aim of this work was to evaluate TCRζ chain gene expression in patients with ITP, thereby to understand the functioning status of T cells and its possible contribution to disease outcome. Methods: SYBR Green based Realtime relative quantitative PCR (qRT-PCR) was used to evaluate TCRζ gene expression in 49 ITP patients and 35 age- and sex-matched control subjects. Results: Patients in acute phase of ITP had a significantly lower TCRζ gene expression compared to those in chronic phase and those of the control group; on the other hand TCRζ gene expression was significantly lower in chronic ITP patients than in controls. Patients with active ITP had a significantly lower TCRζ gene expression compared to those in remission and those of control group (P < 0.001). TCRζ gene expression was significantly lower in ITP patients in remission state in comparison to the control group. Treated ITP patients had a significantly higher TCRζ gene expression compared to untreated patients, however TCRζ gene expression in the treated group was still significantly lower compared to controls (P<0.001). Complete responders had a significantly higher TCRζ gene expression compared to non responders (P<0.001), while no significant difference was found between nonresponders and partial responders as regards TCRζ gene expression (P>0.05). The level of TCRζ gene expression in complete responders was still significantly lower compared to controls (P<0.001). Sequential analyses for TCRζ gene expression in 6 patients with stable disease revealed no significant difference in median TCRζ gene expression values in the 3 consequents analyses (P>0.05). TCRζ gene expression showed no significant correlation with any of the clinical or hematological data. Conclusion: From these data, it could be suggested that downregulation of TCRζ may represent intrinsic defects of potential pathogenetic significance for ITP. Therapy targeted to normalization of TCRζ expression may represent a new strategy for treatment of ITP patients after being validated in clinical trials.
GA, D. (2012). T cell receptor Zeta chain (TCRζ) expression in patients with idiopathic thrombocytopenic purpura. Bulletin of Egyptian Society for Physiological Sciences, 32(1), 47-58. doi: 10.21608/besps.2012.35484
MLA
Dalia GA. "T cell receptor Zeta chain (TCRζ) expression in patients with idiopathic thrombocytopenic purpura". Bulletin of Egyptian Society for Physiological Sciences, 32, 1, 2012, 47-58. doi: 10.21608/besps.2012.35484
HARVARD
GA, D. (2012). 'T cell receptor Zeta chain (TCRζ) expression in patients with idiopathic thrombocytopenic purpura', Bulletin of Egyptian Society for Physiological Sciences, 32(1), pp. 47-58. doi: 10.21608/besps.2012.35484
VANCOUVER
GA, D. T cell receptor Zeta chain (TCRζ) expression in patients with idiopathic thrombocytopenic purpura. Bulletin of Egyptian Society for Physiological Sciences, 2012; 32(1): 47-58. doi: 10.21608/besps.2012.35484